Cargando…

The treatment with pasireotide in Cushing’s disease: effect of long-term treatment on clinical picture and metabolic profile and management of adverse events in the experience of a single center

PURPOSES: Pasireotide is the first medical therapy officially approved for adult patients with Cushing’s disease (CD) experiencing failure of pituitary surgery or not candidates for surgery. The current study aimed at investigating pasireotide effects on clinical picture and metabolic profile in pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Simeoli, C., Ferrigno, R., De Martino, M. C., Iacuaniello, D., Papa, F., Angellotti, D., Pivonello, C., Patalano, R., Negri, M., Colao, A., Pivonello, R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6952330/
https://www.ncbi.nlm.nih.gov/pubmed/31313243
http://dx.doi.org/10.1007/s40618-019-01077-8